Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Daniel P. Petrylak(Yale University), Cristiano Ferrario(Jewish General Hospital), Kim N.(Asian Institute of Technology), Astra M. Liepa(Eli Lilly (United States)), Richard A. Walgren(Eli Lilly (United States)), Nobuaki Matsubara(National Cancer Center Hospital East), Sufia Safina(Republican Oncological Clinical Dispensary), B. Yа. Alekseev(P.A. Hertzen Moscow Oncology Research Institute), Annemie Rutten(GZA Ziekenhuizen Campus Sint-Augustinus), Daniel Castellano(Universidad Complutense de Madrid), Herlinde Dumez, Timothy Clay(Duke Medical Center), Ivor Percent(Florida Cancer Specialists & Research Institute), Michiel S. van der Heijden(Zorginstituut Nederland), Syed A. Hussain(University Hospitals Plymouth NHS Trust), Elizabeth Hovey, Ronald de Wit(Erasmus MC Cancer Institute), Aristotelis Bamias(National and Kapodistrian University of Athens), Ryan C. Widau(Eli Lilly (United States)), Alexandra Drakaki(University of California, Los Angeles), Giampaolo Tortora(University of Naples Federico II), Xavier García del Muro(Institut Català d'Oncologia), İrfan Çiçin(Istinye University), Jae‐Lyun Lee(Ulsan College), Andrey Semenov, Katherine M. Bell‐McGuinn(Memorial Sloan Kettering Cancer Center), Hiroyuki Nishiyama(University of Tsukuba), Hasan Şenol Çoşkun(Akdeniz University), Thomas Powles(Queen Mary University of London), Oday Hamid(Eli Lilly (United States)), Suet-Lai Shirley Wong, Andrea Necchi(Vita-Salute San Raffaele University), Evan Y. Yu(University of Washington), Yen‐Chuan Ou(Tungs' Taichung MetroHarbor Hospital), Susanna Y. Cheng, Alejo Rodríguez‐Vida(Hospital Del Mar), Lajos Géczi(National Institute of Oncology), Marcello Tucci(University of Turin), Hakan Harputluoğlu(Inonu University), Fredrik Laestadius(Centre Oscar Lambret), Miriam Hegemann(Klinikverbund Südwest), Thean Hsiang Tan, Kim Nguyen(Fondazione IRCCS Istituto Nazionale dei Tumori), Siobhan Ng(St John of God Subiaco Hospital), Jean‐Pascal Machiels(Cliniques Universitaires Saint-Luc), Annamaria H. Zimmermann(St Bartholomew's Hospital), Wen-Pin Su(National Cheng Kung University Hospital), Aude Fléchon(Institut Català d'Ornitologia), Avivit Peer(Technion – Israel Institute of Technology), Cora N. Sternberg(Cornell University)
Cited by 177
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k